Analyst Downgrades – Juno Therapeutics (NASDAQ:JUNO) Stock Gets Downgraded By Barclays from Overweight to Equal Weight

ME Staff
-
0

Analyst Ratings For Juno Therapeutics (NASDAQ:JUNO)

Today, Juno Therapeutics (NASDAQ:JUNO) stock was downgraded by Barclays from Overweight to Equal Weight.

Some recent analyst ratings include

  • 1/24/2018-Barclays was Downgraded by analysts at Barclays from a “Overweight ” rating to a ” Equal Weight” rating.
  • 1/23/2018-Leerink Swann was Downgraded by analysts at Leerink Swann from a “Outperform ” rating to a ” Market Perform” rating. They now have a $87.00 price target on the stock, up previously from $56.00 .
  • 1/23/2018-Raymond James Financial was Downgraded by analysts at Raymond James Financial from a “Hold” rating to a “” rating.
  • 1/22/2018-SunTrust Banks Reiterated Rating of Buy .
  • 1/22/2018-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating.
  • 1/22/2018-Guggenheim was Downgraded by analysts at Guggenheim from a “Buy ” rating to a ” Neutral” rating.
  • 1/17/2018-Citigroup was Downgraded by analysts at Citigroup from a “Buy ” rating to a ” Neutral” rating.

Recent Insider Trading Activity For Juno Therapeutics (NASDAQ:JUNO)
Juno Therapeutics (NASDAQ:JUNO) has insider ownership of 15.08% and institutional ownership of 69.96%.

  • On 1/17/2018 Robert Azelby, EVP, sold 29,131 with an average share price of $68.61 per share and the total transaction amounting to $1,998,677.91.
  • On 1/16/2018 Hans Edgar Bishop, CEO, sold 270,250 with an average share price of $46.17 per share and the total transaction amounting to $12,477,442.50.
  • On 1/8/2018 Richard Klausner, Director, sold 12,724 with an average share price of $48.21 per share and the total transaction amounting to $613,424.04.
  • On 12/21/2017 Richard Klausner, Director, sold 36,000 with an average share price of $44.76 per share and the total transaction amounting to $1,611,360.00.
  • On 12/21/2017 Steve Harr, CFO, sold 8,750 with an average share price of $44.76 per share and the total transaction amounting to $391,650.00.
  • On 12/18/2017 Robert Azelby, EVP, sold 1,816 with an average share price of $44.96 per share and the total transaction amounting to $81,647.36.
  • On 11/2/2017 Robert Azelby, EVP, sold 6,666 with an average share price of $54.95 per share and the total transaction amounting to $366,296.70.

Recent Trading Activity for Juno Therapeutics (NASDAQ:JUNO)
Shares of Juno Therapeutics closed the previous trading session at 85.98 up +0.12 0.14% with 85.73999786376953 shares trading hands.